A breast cancer vaccine could be closer to reality, according to Cleveland Clinic, as its researchers have announced some encouraging results. Researchers and doctors weigh in.

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

UCSF researchers develop customizable SNIPR sensors that activate engineered cells only near tumors, promising precise cancer ...

The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

Immunology is the study of the immune system and its defense mechanisms, and immuno-oncology is when cancer patients are ...

In a small subset of those patients, the combination resulted in a strong response with tumor shrinkage and no disease ...

Researchers have created a groundbreaking antibody that combines targeting, delivery, and immune activation to treat cancer, ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

A new study out of Harvard Medical School is opening the door for cancer patients with a rare but dangerous heart condition ...

Nine of 11 patients in new brain cancer trial saw their tumors shrink by at least half. One really beat the odds.

LOUISVILLE, Ky. -- More than half of patients with newly diagnosed metastatic kidney cancer responded to a novel drug ...

Peter Hosein, M.D., a medical oncologist specializing in pancreatic cancer at Sylvester Comprehensive Cancer Center, ...